BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present a company overview at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011, at 9:30 a.m. Pacific Time / 12:30 p.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website, www.seattlegenetics.com, under the “Investors and News” section.
About Seattle Genetics
Seattle Genetics is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company recently reported positive data from a pivotal Hodgkin lymphoma trial and phase II systemic anaplastic large cell lymphoma (ALCL) trial with its lead product candidate, brentuximab vedotin. Seattle Genetics plans to submit a Biologics License Application for brentuximab vedotin to the U.S. Food and Drug Administration for both relapsed or refractory Hodgkin lymphoma and ALCL in the first quarter of 2011. Brentuximab vedotin is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has four other clinical-stage programs: SGN-75, ASG-5ME, dacetuzumab (SGN-40) and SGN-70. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium: The Takeda Oncology Company and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at www.seattlegenetics.com.
Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
KEYWORDS: United States North America California Washington
INDUSTRY KEYWORDS: Health Biotechnology Oncology Pharmaceutical